May 2024
1. DITTRICH A, Westman E, Shams S, Skillback T, et al
   Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study.
   Neurology. 2024;102:e209402.
   

   >> Share

   
   
2. VASSILAKI M, Pittock RR, Aakre JA, Castillo AM, et al
   Author Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
   Neurology. 2024;102:e209377.
   

   >> Share

   
   
3. CHIABOTTI PS, Rouaud O, Allali G
   Reader Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
   Neurology. 2024;102:e209375.
   

   >> Share

   
   
4. LEWIS A, Galetta S
   Editors' Note: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
   Neurology. 2024;102:e209376.
   

   >> Share

   
   
5. WOOD ALEXANDER M, Wu CY, Coughlan GT, Puri T, et al
   Associations Between Age at Menopause, Vascular Risk, and 3-Year Cognitive Change in the Canadian Longitudinal Study on Aging.
   Neurology. 2024;102:e209298.
   

   >> Share

   
   
6. GRASSET L, Bouteloup V, Cacciamani F, Pellegrin I, et al
   Associations Between Blood-Based Biomarkers and Cognitive and Functional Trajectories Among Participants of the MEMENTO Cohort.
   Neurology. 2024;102:e209307.
   

   >> Share

   
   April 2024
7. BUCKLEY RF, Schindler SE
   Lower Accuracy Alzheimer Disease Blood Tests Will Never Be "Ready for Prime Time".
   Neurology. 2024;102:e209295.
   

   >> Share

   
   
8. BOUTELOUP V, Pellegrin I, Dubois B, Chene G, et al
   Explaining the Variability of Alzheimer Disease Fluid Biomarker Concentrations in Memory Clinic Patients Without Dementia.
   Neurology. 2024;102:e209219.
   

   >> Share

   
   
9. RAJAN KB, Mcaninch EA, Wilson RS, Dhana A, et al
   Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.
   Neurology. 2024;102:e209168.
   

   >> Share

   
   
10. ASKEN BM, Tanner JA, Vandevrede L, Apple A, et al
    Linking Type and Extent of Head Trauma to Cavum Septum Pellucidum in Older Adults With and Without Alzheimer Disease and Related Dementias.
    Neurology. 2024;102:e209183.
    

    >> Share

    
    
11. NELSON SE, Lopez OL
    Lecanemab for Alzheimer Disease: Is It Worth It?
    Neurology. 2024;102:e209265.
    

    >> Share

    
    
12. NADEAU SE
    Lecanemab Questions.
    Neurology. 2024;102:e209320.
    

    >> Share

    
    
13. NGUYEN HV, Mital S, Knopman DS, Alexander GC, et al
    Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease.
    Neurology. 2024;102:e209218.
    

    >> Share

    
    
14. ALOSCO ML, Tartaglia MC
    Repetitive Blast Injury and CSF Alzheimer Disease Biomarkers: Navigating a Complex Narrative.
    Neurology. 2024;102:e209294.
    

    >> Share

    
    
15. LI G, Iliff J, Shofer J, Mayer CL, et al
    CSF beta-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury.
    Neurology. 2024;102:e209197.
    

    >> Share

    
    
16. OVEISGHARAN S, Grodstein F, Evia AM Jr, James BD, et al
    Association of Age-Related Neuropathologic Findings at Autopsy With a Claims-Based Epilepsy Diagnosis in Older Adults.
    Neurology. 2024;102:e209172.
    

    >> Share

    
    
17. WEINSTEIN G, Kojis DJ, Ghosh S, Beiser AS, et al
    Association of Neurotrophic Factors at Midlife With In Vivo Measures of beta-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults.
    Neurology. 2024;102:e209198.
    

    >> Share

    
    
18. LU Y, Pike JR, Hoogeveen R, Walker K, et al
    Nonalcoholic Fatty Liver Disease and Longitudinal Change in Imaging and Plasma Biomarkers of Alzheimer Disease and Vascular Pathology.
    Neurology. 2024;102:e209203.
    

    >> Share

    
    
19. BUCHMAN AS, Yu L, Klein HU, Zammit AR, et al
    Glycoproteome-Wide Discovery of Cortical Glycoproteins That May Provide Cognitive Resilience in Older Adults.
    Neurology. 2024;102:e209223.
    

    >> Share

    
    
20. CAI Y, Shi D, Lan G, Chen L, et al
    Association of beta-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia.
    Neurology. 2024;102:e209205.
    

    >> Share

    
    March 2024
21. HONIG M, Altomare D, Caprioglio C, Collij L, et al
    Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease.
    Neurology. 2024;102:e208053.
    

    >> Share

    
    
22. ACKLEY S, Calmasini C, Bouteloup V, Hill-Jarrett TG, et al
    Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort.
    Neurology. 2024;102:e208054.
    

    >> Share

    
    
23. GUO C, Harshfield EL, Markus HS
    Sleep Characteristics and Risk of Stroke and Dementia: An Observational and Mendelian Randomization Study.
    Neurology. 2024;102:e209141.
    

    >> Share

    
    
24. FLEISHER AS, Munsie LM, Perahia DGS, Andersen SW, et al
    Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
    Neurology. 2024;102:e208061.
    

    >> Share

    
    
25. CHRISTENSEN GM, Li Z, Liang D, Ebelt S, et al
    Association of PM(2.5) Exposure and Alzheimer Disease Pathology in Brain Bank Donors-Effect Modification by APOE Genotype.
    Neurology. 2024;102:e209162.
    

    >> Share

    
    February 2024
26. HILL-JARRETT TG, Choi M, Buto PT, Miramontes S, et al
    Associations of Everyday and Lifetime Experiences of Discrimination With Willingness to Undergo Alzheimer Disease Predictive Testing.
    Neurology. 2024;102:e208005.
    

    >> Share

    
    
27. PASE MP, Himali JJ, Puerta R, Beiser AS, et al
    Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia.
    Neurology. 2024;102:e208075.
    

    >> Share

    
    
28. YASAR S, Nidadavolu L
    Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention.
    Neurology. 2024;102:e209180.
    

    >> Share

    
    
29. ADESUYAN M, Jani YH, Alsugeir D, Howard R, et al
    Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study.
    Neurology. 2024;102:e209131.
    

    >> Share

    
    
30. SHINOTOH H
    White Matter Neuroinflammation Matters in Early Alzheimer Disease.
    Neurology. 2024;102:e208090.
    

    >> Share

    
    
31. TARAWNEH R
    YKL-40 as a New Plasma Biomarker for Dementia Risk: Are We There Yet?
    Neurology. 2024;102:e209145.
    

    >> Share

    
    
32. HARDY J, Schott JM
    Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities.
    Neurology. 2024;102:e208096.
    

    >> Share

    
    
33. LOOMIS SJ, Miller R, Castrillo-Viguera C, Umans K, et al
    Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
    Neurology. 2024;102:e207919.
    

    >> Share

    
    
34. CHOLERTON B, Latimer CS, Crane PK, Corrada MM, et al
    Neuropathologic Burden and Dementia in Nonagenarians and Centenarians.
    Neurology. 2024;102:e208060.
    

    >> Share

    
    
35. PARK SY, Setiawan VW, Crimmins EM, White LR, et al
    Racial and Ethnic Differences in the Population-Attributable Fractions of Alzheimer Disease and Related Dementias.
    Neurology. 2024;102:e208116.
    

    >> Share

    
    
36. WANG Q, Schindler SE, Chen G, Mckay NS, et al
    Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging.
    Neurology. 2024;102:e208013.
    

    >> Share

    
    
37. COUSINS KAQ, Irwin DJ, Tropea TF, Rhodes E, et al
    Evaluation of ATN(PD) Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
    Neurology. 2024;102:e208033.
    

    >> Share

    
    January 2024
38. CASTILHOS RM, Snitz BE
    Longitudinal Cognitive Decline in Alzheimer Disease Prevention Trials.
    Neurology. 2024;102:e208067.
    

    >> Share

    
    
39. DUBBELMAN MA, Hendriksen HMA, Harrison JE, Vijverberg EGB, et al
    Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups.
    Neurology. 2024;102:e207978.
    

    >> Share

    
    
40. LOPEZ OL, Villemagne VL, Chang YF, Cohen AD, et al
    Association Between beta-Amyloid Accumulation and Incident Dementia in Individuals 80 Years or Older Without Dementia.
    Neurology. 2024;102:e207920.
    

    >> Share

    
    
41. PEROSA V, Zanon Zotin MC, Schoemaker D, Sveikata L, et al
    Association Between Hippocampal Volumes and Cognition in Cerebral Amyloid Angiopathy.
    Neurology. 2024;102:e207854.
    

    >> Share

    
    
42. ZANON ZOTIN MC, Makkinejad N, Schneider JA, Arfanakis K, et al
    Sensitivity and Specificity of the Boston Criteria Version 2.0 for the Diagnosis of Cerebral Amyloid Angiopathy in a Community-Based Sample.
    Neurology. 2024;102:e207940.
    

    >> Share

    
    December 2023
43. HANSEEUW BJ, Jacobs HIL, Schultz AP, Buckley RF, et al
    Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults.
    Neurology. 2023;101:e2533-e2544.
    

    >> Share

    
    November 2023
44. ZHOU Z, Ryan J, Tonkin AM, Zoungas S, et al
    Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study.
    Neurology. 2023;101:e2288-e2299.
    

    >> Share

    
    
45. YOON SH, Kim HK, Lee JH, Chun JH, et al
    Association of Sleep Disturbances With Brain Amyloid and Tau Burden, Cortical Atrophy, and Cognitive Dysfunction Across the AD Continuum.
    Neurology. 2023;101:e2162-e2171.
    

    >> Share

    
    
46. FERGUSON EL, Zimmerman SC, Jiang C, Choi M, et al
    Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan.
    Neurology. 2023;101:e2172-e2184.
    

    >> Share

    
    
47. NELSON PT, Jicha GA
    Early Hippocampal Atrophy Is an Important Signal for Clinicians, but Not Necessarily a Harbinger of Alzheimer Disease.
    Neurology. 2023 Nov 15:10.1212/WNL.0000000000208071.
    

    >> Share

    
    
48. PITTOCK RR, Aakre JA, Castillo AM, Ramanan VK, et al
    Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Neurology. 2023;101:e1837-e1849.
    

    >> Share

    
    
49. HOWE MD, Rabinovici GD, Salloway SP
    Real-World Application of Anti-beta-Amyloid Monoclonal Antibodies: Untangling Eligibility.
    Neurology. 2023;101:811-812.
    

    >> Share

    
    October 2023
50. THEIS H, Bischof GN, Bruggemann N, Dargvainiene J, et al
    In Vivo Measurement of Tau Depositions in Anti-IgLON5 Disease Using (18)F-PI-2620 PET.
    Neurology. 2023 Oct 25:10.1212/WNL.0000000000207870.
    

    >> Share

    
    
51. ALAM JJ, Maruff P, Doctrow SR, Chu HM, et al
    Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
    Neurology. 2023;101:e1708-e1717.
    

    >> Share

    
    
52. SANTAMARIA BA, Corroza J, Sanchez-Ruiz de Gordoa J, Cabello C, et al
    Association of Blood-Based DNA Methylation Markers With Late-Onset Alzheimer Disease: A Potential Diagnostic Approach.
    Neurology. 2023 Oct 12:10.1212/WNL.0000000000207865.
    

    >> Share

    
    
53. STARK M, Wolfsgruber S, Kleineidam L, Frommann I, et al
    Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline.
    Neurology. 2023 Oct 11:10.1212/WNL.0000000000207844.
    

    >> Share

    
    
54. GONZALES MM, Vela G, Philip V, Trevino H, et al
    Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort.
    Neurology. 2023;101:e1531-e1541.
    

    >> Share

    
    
55. OVEISGHARAN S, Yu L, Agrawal S, Nag S, et al
    Relation of Motor Impairments to Neuropathologic Changes of Limbic-Predominant Age-Related TDP-43 Encephalopathy in Older Adults.
    Neurology. 2023;101:e1542-e1553.
    

    >> Share

    
    
56. BONOMI S, Samara A, Balestra N, Padalia A, et al
    Teaching NeuroImage: Severe Amyloid-Related Imaging Abnormalities After Anti-beta-Amyloid Monoclonal Antibody Treatment.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207927.
    

    >> Share

    
    
57. BRENNER S
    Reader Response: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
    Neurology. 2023;101:633-634.
    

    >> Share

    
    
58. OVEISGHARAN S, Bennett DA
    Author Response: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
    Neurology. 2023;101:634.
    

    >> Share

    
    
59. GANESH A, Galetta S
    Editors' Note: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
    Neurology. 2023;101:633.
    

    >> Share

    
    
60. LEWIS A, Gupta A, Oh I, Schindler SE, et al
    Association Between Socioeconomic Factors, Race, and Use of a Specialty Memory Clinic.
    Neurology. 2023;101:e1424-e1433.
    

    >> Share

    
    September 2023
61. GOODSMITH MS, Wroblewski KE, Schumm LP, McClintock MK, et al
    Association of APOE epsilon4 Status With Long-term Declines in Odor Sensitivity, Odor Identification, and Cognition in Older US Adults.
    Neurology. 2023;101:e1341-e1350.
    

    >> Share

    
    
62. COOMANS EM, de Koning LA, Rikken RM, Verfaillie SC, et al
    Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207794.
    

    >> Share

    
    
63. MALPETTI M, Rabinovici GD
    From Clinical Trials to Memory Clinics, tau-PET Visual Reads Can Help Diagnosis and Patient Stratification.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207935.
    

    >> Share

    
    
64. YAMAGUCHI S, Murakami T, Satoh M, Komiyama T, et al
    Associations of Dental Health With the Progression of Hippocampal Atrophy in Community-Dwelling Individuals: The Ohasama Study.
    Neurology. 2023;101:e1056-e1068.
    

    >> Share

    
    August 2023
65. MONTEIRO C, Toth B, Brunstein F, Bobbala A, et al
    A Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants with Mild-to-Moderate Alzheimer's Disease (Lauriet).
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207663.
    

    >> Share

    
    
66. EDLAND SD, Ucsd, Llibre-Guerra JJ
    Semorinemab in Mild to Moderate Alzheimer Disease: A Glimmer of Hope Though Cautions Remain.
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207861.
    

    >> Share

    
    
67. KAMAL F, Morrison C, Maranzano J, Zeighami Y, et al
    White Matter Hyperintensity Trajectories in Patients With Progressive and Stable Mild Cognitive Impairment.
    Neurology. 2023;101:e815-e824.
    

    >> Share

    
    
68. PARNETTI L, Bellomo G
    Advances in Diagnosis and Prognosis of Parkinson Disease: Value of Cerebrospinal Fluid Proteomics.
    Neurology. 2023 Aug 16:10.1212/WNL.0000000000207724.
    

    >> Share

    
    
69. KAWADA T
    Reader Response: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
    Neurology. 2023;101:333-334.
    

    >> Share

    
    
70. PROSSER L
    Author Response: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
    Neurology. 2023;101:334.
    

    >> Share

    
    
71. LEWIS A, Galetta S
    Editors' Note: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
    Neurology. 2023;101:333.
    

    >> Share

    
    
72. RAMANAN VK, Graff-Radford J, Syrjanen J, Shir D, et al
    Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort.
    Neurology. 2023 Aug 14:10.1212/WNL.0000000000207675.
    

    >> Share

    
    
73. CATHARINA BOON BD, Labuzan S, Peng Z, Matchett B, et al
    Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared to Corticolimbic Alzheimer Disease Subtypes.
    Neurology. 2023 Aug 14:10.1212/WNL.0000000000207685.
    

    >> Share

    
    
74. LAM AD
    Linking Late-Onset Epilepsy With Alzheimer Disease: Insights From Plasma Amyloid Measurements.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207683.
    

    >> Share

    
    
75. JOHNSON EL, Sullivan KJ, Schneider ALC, Simino J, et al
    Association of Plasma Abeta 42/40 Ratio and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207635.
    

    >> Share

    
    
76. HADDAD A, Brunel G, Indart S, Paquet C, et al
    A Patient With the Posterior Variant of Alzheimer Disease Plays Table Tennis: Blindsight and Pingpong.
    Neurology. 2023 Aug 3:10.1212/WNL.0000000000207650.
    

    >> Share

    
    July 2023
77. DURCAN R, Roberts G, Hamilton CA, Donaghy PC, et al
    Serial Nigrostriatal Dopaminergic Imaging in Mild Cognitive Impairment With Lewy Bodies, Alzheimer Disease, and Age-Matched Controls.
    Neurology. 2023 Jul 31:10.1212/WNL.0000000000207621.
    

    >> Share

    
    
78. RAMANAN VK, Armstrong MJ, Choudhury P, Coerver K, et al
    Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology.
    Neurology. 2023 Jul 26:10.1212/WNL.0000000000207757.
    

    >> Share

    
    
79. PROKOPIOU PC, Engels-Dominguez N, Schultz AP, Sepulcre J, et al
    Association of Novelty-Related Locus Coeruleus Function With Entorhinal Tau Deposition and Memory Decline in Preclinical Alzheimer Disease.
    Neurology. 2023 Jul 25:10.1212/WNL.0000000000207646.
    

    >> Share

    
    
80. KARCESKI S, Antonopoulos M
    Biomarkers in Alzheimer Disease: A Review.
    Neurology. 2023;101:e461-e463.
    

    >> Share

    
    
81. ANDRE C, Kuhn E, Rehel S, Ourry V, et al
    Association of Sleep-Disordered Breathing and Medial Temporal Lobe Atrophy in Cognitively Unimpaired Amyloid-Positive Older Adults.
    Neurology. 2023;101:e370-e385.
    

    >> Share

    
    
82. ALCOLEA D, Beeri MS, Rojas JC, Gardner RC, et al
    Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.
    Neurology. 2023;101:172-180.
    

    >> Share

    
    
83. BURKE JF, Richard S, Langa KM, Albin RL, et al
    Lecanemab: Looking Before We Leap.
    Neurology. 2023 Jul 21:10.1212/WNL.0000000000207505.
    

    >> Share

    
    
84. SHIR D, Pham NTT, Botha H, Koga S, et al
    Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome.
    Neurology. 2023;101:e289-e299.
    

    >> Share

    
    
85. DITTRICH A, Ashton NJ, Zetterberg H, Blennow K, et al
    Association of Chronic Kidney Disease With Plasma NfL and Other Biomarkers of Neurodegeneration: The H70 Birth Cohort Study in Gothenburg.
    Neurology. 2023;101:e277-e288.
    

    >> Share

    
    
86. MOSER ED, Manemann SM, Larson NB, St Sauver JL, et al
    Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease Related Dementias.
    Neurology. 2023 Jul 5:10.1212/WNL.0000000000207595.
    

    >> Share

    
    
87. BARBA L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, et al
    CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease.
    Neurology. 2023;101:e50-e62.
    

    >> Share

    
    
88. FERREIRA PCL, Ferrari-Souza JP, Tissot C, Bellaver B, et al
    Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials.
    Neurology. 2023;101:38-45.
    

    >> Share

    
    
89. LICHTER DG, Hershey L
    Proposal to Add FDG-PET as an Outcome Measure for Clinical Trials in Patients With Prodromal Lewy Body Dementia.
    Neurology. 2023 Jul 3:10.1212/WNL.0000000000207498.
    

    >> Share

    
    June 2023
90. KNOPMAN DS, Hershey L
    Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift.
    Neurology. 2023 Jun 9:10.1212/WNL.0000000000207438.
    

    >> Share

    
    May 2023
91. GROBER E, Petersen KK, Lipton RB, Hassenstab J, et al
    Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals.
    Neurology. 2023;100:e2279-e2289.
    

    >> Share

    
    
92. FANG Y, Si X, Wang J, Wang Z, et al
    Alzheimer Disease and Epilepsy: A Mendelian Randomization Study.
    Neurology. 2023 May 24:10.1212/WNL.0000000000207423.
    

    >> Share

    
    
93. LUO J, Ma Y, Agboola FJ, Grant E, et al
    Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Lifespan.
    Neurology. 2023 May 18:10.1212/WNL.0000000000207378.
    

    >> Share

    
    
94. DIAZ-GALVAN P, Przybelski SA, Lesnick TG, Schwarz CG, et al
    beta-Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies.
    Neurology. 2023 May 18:10.1212/WNL.0000000000207393.
    

    >> Share

    
    
95. ALVES F, Kalinowski P, Ayton S
    Accelerated Brain Volume Loss Caused by Anti-beta-Amyloid Drugs: A Systematic Review and Meta-analysis.
    Neurology. 2023;100:e2114-e2124.
    

    >> Share

    
    
96. DU J, Li A, Shi D, Chen X, et al
    Association of APOE4, Osteoarthritis, beta-Amyloid, and Tau Accumulation in Primary Motor and Somatosensory Regions in Alzheimer Disease.
    Neurology. 2023 May 15:10.1212/WNL.0000000000207369.
    

    >> Share

    
    
97. BUTLER PAGNOTTI RM, Pudumjee SB, Cross CL, Miller JB, et al
    Cognitive and Clinical Characteristics of Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy.
    Neurology. 2023;100:e2027-e2035.
    

    >> Share

    
    
98. CICOGNOLA C, Mattsson-Carlgren N, van Westen D, Zetterberg H, et al
    Associations of CSF PDGFRbeta With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
    Neurology. 2023 May 3:10.1212/WNL.0000000000207358.
    

    >> Share

    
    
99. SINHA N, Gugger JJ
    Towards a Patient-Specific Readout of Neurodegeneration: The Case for Spatial Normative Modeling in Alzheimer Disease.
    Neurology. 2023 May 1:10.1212/WNL.0000000000207280.
    

    >> Share

    
    
100. VERDI S, Kia SM, Yong KXX, Tosun D, et al
     Revealing Individual Neuroanatomical Heterogeneity in Alzheimer Disease Using Neuroanatomical Normative Modeling.
     Neurology. 2023 May 1:10.1212/WNL.0000000000207298.
     

     >> Share

     
     April 2023
101. GERTJE EC, Janelidze S, van Westen D, Cullen N, et al
     Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.
     Neurology. 2023;100:e1812-e1824.
     

     >> Share

     
     
102. KUHN E, Perrotin A, La Joie R, Touron E, et al
     Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum.
     Neurology. 2023 Apr 21:10.1212/WNL.0000000000207338.
     

     >> Share

     
     
103. INSEL PS, Kumar A, Hansson O, Mattsson-Carlgren N, et al
     Genetic Moderation of the Association of beta-Amyloid With Cognition and MRI in Alzheimer Disease.
     Neurology. 2023 Apr 21:10.1212/WNL.0000000000207305.
     

     >> Share

     
     
104. BRUMM MC, Pierz KA, Lafontant DE, Caspell-Garcia C, et al
     Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older.
     Neurology. 2023;100:e1691-e1701.
     

     >> Share

     
     
105. YANG Z, Wei C, Li X, Yuan J, et al
     Association Between Regular Laxative Use and Incident Dementia in UK Biobank Participants.
     Neurology. 2023;100:e1702-e1711.
     

     >> Share

     
     
106. TIAN J, Raghavan Pillai SK, Reid RI, Przybelski SA, et al
     White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease.
     Neurology. 2023 Apr 17:10.1212/WNL.0000000000207250.
     

     >> Share

     
     
107. BRODTMANN A, Beversdorf DQ
     The Alzheimer Disconnectome.
     Neurology. 2023 Apr 17:10.1212/WNL.0000000000207303.
     

     >> Share

     
     
108. 
     Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-beta-Amyloid Immunotherapy: A Meta-analysis.
     Neurology. 2023 Apr 4:10.1212/WNL.0000000000207344.
     

     >> Share

     
     
109. WANG Y, Liang J, Fang Y, Yao D, et al
     Burden of Common Neurologic Diseases in Asian Countries, 1990-2019: An Analysis for the Global Burden of Disease Study 2019.
     Neurology. 2023 Apr 4:10.1212/WNL.0000000000207218.
     

     >> Share

     
     March 2023
110. BARKHOF F, Knopman DS
     Brain Shrinkage in Anti-beta-Amyloid Alzheimer Trials: Neurodegeneration or Pseudo-atrophy?
     Neurology. 2023 Mar 27:10.1212/WNL.0000000000207268.
     

     >> Share

     
     
111. ZHANG Y, Liu X, Wiggins KL, Kurniansyah N, et al
     Association of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function: A Meta-analysis of Community-Based Cohorts.
     Neurology. 2023 Mar 16:10.1212/WNL.0000000000207157.
     

     >> Share

     
     
112. AGARWAL P, Leurgans SE, Agrawal S, Aggarwal N, et al
     Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology.
     Neurology. 2023 Mar 8:10.1212/WNL.0000000000207176.
     

     >> Share

     
     
113. KURIHARA M, Komatsu H, Sengoku R, Shibukawa M, et al
     CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease.
     Neurology. 2023;100:e1009-e1019.
     

     >> Share

     
     
114. CHAPMAN S, Renteria MA, Dworkin JD, Garriga SM, et al
     Association of Subjective Cognitive Decline With Progression to Dementia in a Cognitively Unimpaired Multiracial Community Sample.
     Neurology. 2023;100:e1020-e1027.
     

     >> Share

     
     February 2023
115. TIAN Q, An Y, Kitner-Triolo MH, Davatzikos C, et al
     Associations of Olfaction With Longitudinal Trajectories of Brain Volumes and Neuropsychological Function in Older Adults.
     Neurology. 2023;100:e964-e974.
     

     >> Share

     
     
116. SARTO J, Ruiz-Garcia R, Guillen N, Ramos-Campoy O, et al
     Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort.
     Neurology. 2023;100:e860-e873.
     

     >> Share

     
     
117. FERREIRA D, Przybelski SA, Lesnick TG, Schwarz CG, et al
     Cross-sectional Associations of beta-Amyloid, Tau, and Cerebrovascular Biomarkers With Neurodegeneration in Probable Dementia With Lewy Bodies.
     Neurology. 2023;100:e846-e859.
     

     >> Share

     
     
118. MCCUSKER EA, Loy CT
     Scientific, Ethical, and Practical Considerations for the Testing and Disclosure of Alzheimer Disease Biomarkers.
     Neurology. 2023 Feb 15:10.1212/WNL.0000000000207199.
     

     >> Share

     
     
119. GECZI K
     Right Brain: Oriented to Self.
     Neurology. 2023;100:349-350.
     

     >> Share

     
     January 2023
120. LARGENT EA, Grill J, O'Brien K, Wolk D, et al
     Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.
     Neurology. 2023 Jan 31:10.1212/WNL.0000000000206891.
     

     >> Share

     
     
121. OVEISGHARAN S, Yang J, Yu L, Burba D, et al
     Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
     Neurology. 2023 Jan 25:10.1212/WNL.0000000000206833.
     

     >> Share

     
     
122. 
     Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease.
     Neurology. 2023 Jan 24:10.1212/WNL.0000000000201690.
     

     >> Share

     
     
123. 
     Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.
     Neurology. 2023 Jan 23:10.1212/WNL.0000000000206876.
     

     >> Share

     
     
124. OHRFELT A, Benedet AL, Ashton NJ, Kvartsberg H, et al
     Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
     Neurology. 2023;100:e275-e285.
     

     >> Share

     
     
125. ALTY JE, Bindoff AD, Stuart KE, Roccati E, et al
     Sex-Specific Protective Effects of Cognitive Reserve on Age-Related Cognitive Decline: A 5-Year Prospective Cohort Study.
     Neurology. 2023;100:e211-e219.
     

     >> Share

     
     
126. SAJJADI SA, Bukhari S, Scambray KA, Yan R, et al
     Impact and Risk Factors of Limbic Predominant Age-Related TDP-43 Encephalopathy Neuropathologic Change in an Oldest-Old Cohort.
     Neurology. 2023;100:e203-e210.
     

     >> Share

     
     
127. GLANS I, Sonestedt E, Nagga K, Gustavsson AM, et al
     Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period.
     Neurology. 2023;100:e28-e37.
     

     >> Share

     
     December 2022
128. BARRIO IR, Miki Y, Jaunmuktane ZT, Warner T, et al
     Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy.
     Neurology. 2022 Dec 16:10.1212/WNL.0000000000201659.
     

     >> Share

     
     November 2022
129. RAJAN K, McAninch EA, Aggarwal N, Barnes LL, et al
     Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample.
     Neurology. 2022 Nov 29:10.1212/WNL.0000000000201289.
     

     >> Share

     
     
130. HUANG J, Su B, Karhunen V, Gill D, et al
     Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization.
     Neurology. 2022 Nov 16. pii: WNL.0000000000201489.
     

     >> Share

     
     
131. ROYALL DR
     Reader Response: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
     Neurology. 2022;99:918-919.
     

     >> Share

     
     
132. GANESH A, Galetta S
     Editors' Note: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
     Neurology. 2022;99:918.
     

     >> Share

     
     
133. QIU WQ, Tao Q, Akhter-Khan SC
     Author Response: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
     Neurology. 2022;99:919.
     

     >> Share

     
     
134. YU L, Hsieh YC, Pearse RV, Wang Y, et al
     Association of AK4 Protein From Stem Cell-Derived Neurons With Cognitive Reserve: An Autopsy Study.
     Neurology. 2022;99:e2264-e2274.
     

     >> Share

     
     
135. PROSSER L, MacDougall A, Sudre CH, Manning EN, et al
     Predicting Cognitive Decline in Nondemented Elders Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
     Neurology. 2022 Nov 10. pii: WNL.0000000000201572.
     

     >> Share

     
     
136. ROSENBERG A, Ohlund-Wistbacka U, Hall A, Bonnard A, et al
     beta-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.
     Neurology. 2022;99:e2102-e2113.
     

     >> Share

     
     
137. TANGEN GG, Nilsson MH, Stomrud E, Palmqvist S, et al
     Spatial Navigation and Its Association With Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia.
     Neurology. 2022;99:e2081-e2091.
     

     >> Share

     
     
138. GHAHREMANI M, Wang M, Chen HY, Zetterberg H, et al
     Plasma P-Tau181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease.
     Neurology. 2022 Nov 2. pii: WNL.0000000000201517.
     

     >> Share

     
     October 2022
139. MICHIELS L, Thijs L, Mertens N, Sunaert S, et al
     In Vivo Detection of Neurofibrillary Tangles by 18F-MK-6240 PET/MR in Patients With Ischemic Stroke.
     Neurology. 2022 Oct 27. pii: WNL.0000000000201344.
     

     >> Share

     
     
140. SUCHY-DICEY AM, Oziel K, Sawyer C, Olufadi Y, et al
     Educational and Clinical Associations With Longitudinal Cognitive Function and Brain Imaging in American Indians: The Strong Heart Study.
     Neurology. 2022 Oct 26. pii: WNL.0000000000201261.
     

     >> Share

     
     
141. QUISPIALAYA KM, Therriault J, Aliaga A, Zimmermann M, et al
     Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases.
     Neurology. 2022 Oct 20. pii: WNL.0000000000201198.
     

     >> Share

     
     
142. PLANCHE V, Bouteloup V, Pellegrin I, Mangin JF, et al
     Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort.
     Neurology. 2022 Oct 19. pii: WNL.0000000000201479.
     

     >> Share

     
     
143. GREENBERG BD, Pettigrew C, Soldan A, Wang J, et al
     CSF Alzheimer Disease Biomarkers: Time-Varying Relationships With MCI Symptom Onset and Associations With Age, Sex, and ApoE4.
     Neurology. 2022;99:e1640-e1650.
     

     >> Share

     
     September 2022
144. 
     Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease.
     Neurology. 2022 Sep 30. pii: WNL.0000000000201298.
     

     >> Share

     
     
145. GALE SA, Heidebrink J, Grill J, Graff-Radford J, et al
     Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care.
     Neurology. 2022 Sep 30. pii: WNL.0000000000201347.
     

     >> Share

     
     
146. BEVERSDORF DQ, Scharre DW
     The Dilemma of the Clinical Utility of Alzheimer Biomarker Evaluation in Everyday Clinical Practice: My Favorite PETs.
     Neurology. 2022 Sep 29. pii: WNL.0000000000201478.
     

     >> Share

     
     
147. ROMERO JR, Pinheiro A, Aparicio HJ, DeCarli CS, et al
     MRI Visible Perivascular Spaces and Risk of Incident Dementia: The Framingham Heart Study.
     Neurology. 2022 Sep 29. pii: WNL.0000000000201293.
     

     >> Share

     
     
148. DEMNITZ-KING H, Gonneaud J, Klimecki OM, Chocat A, et al
     Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults.
     Neurology. 2022;99:e1422-e1431.
     

     >> Share

     
     
149. SUGDEN K, Caspi A, Elliott ML, Bourassa KJ, et al
     Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia.
     Neurology. 2022;99:e1402-e1413.
     

     >> Share

     
     
150. CONSTANT AB, Basavaraju R, France J, Honig LS, et al
     Longitudinal Patterns of Cortical Atrophy on MRI in Patients With Alzheimer Disease With and Without Lewy Body Pathology.
     Neurology. 2022 Sep 19. pii: WNL.0000000000200947.
     

     >> Share

     
     
151. KAMAGATA K, Andica C, Takabayashi K, Saito Y, et al
     Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease.
     Neurology. 2022 Sep 19. pii: WNL.0000000000201300.
     

     >> Share

     
     
152. HICKS AJ, Ponsford JL, Spitz G, Dore V, et al
     beta-Amyloid and Tau Imaging in Chronic Traumatic Brain Injury: A Cross-sectional Study.
     Neurology. 2022;99:e1131-e1141.
     

     >> Share

     
     
153. ZETTERBERG H, Schott JM
     Objectifying Subjective Cognitive Decline: The Prognostic Role of Alzheimer Biomarkers.
     Neurology. 2022 Sep 2. pii: WNL.0000000000201172.
     

     >> Share

     
     August 2022
154. QUILICO COUSINS KA, Arezoumandan S, Shellikeri S, Ohm D, et al
     CSF Biomarkers of Alzheimer Disease in Patients With Concomitant alpha-Synuclein Pathology.
     Neurology. 2022 Aug 30. pii: WNL.0000000000201202.
     

     >> Share

     
     
155. DUBBELMAN MA, Verrijp M, Terwee CB, Jutten RJ, et al
     Determining the Minimal Important Change of Everyday Functioning in Dementia: Pursuing Clinical Meaningfulness.
     Neurology. 2022;99:e954-e964.
     

     >> Share

     
     
156. JEONG SY, Suh CH, Shim WH, Lim JS, et al
     Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-beta-amyloid Immunotherapy: A Meta-analysis.
     Neurology. 2022 Aug 29. pii: WNL.0000000000201019.
     

     >> Share

     
     
157. SALMON DP, Smirnov DS, Coughlin DG, Hamilton JM, et al
     Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy Bodies or Alzheimer Disease.
     Neurology. 2022 Aug 26. pii: WNL.0000000000201068.
     

     >> Share

     
     
158. ROSTAMZADEH A, Bohr L, Wagner M, Baethge C, et al
     Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-Analysis.
     Neurology. 2022 Aug 26. pii: WNL.0000000000201072.
     

     >> Share

     
     
159. BILLETTE OV, Ziegler G, Aruci M, Schutze H, et al
     Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease.
     Neurology. 2022;99:e775-e788.
     

     >> Share

     
     
160. JEONG SH, Cha J, Park M, Jung JH, et al
     Association of Enlarged Perivascular Spaces With Amyloid Burden and Cognitive Decline in Alzheimer Disease Continuum.
     Neurology. 2022 Aug 19. pii: WNL.0000000000200989.
     

     >> Share

     
     
161. DUMURGIER J, Sabia S, Zetterberg H, Teunissen CE, et al
     A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging.
     Neurology. 2022;99:e669-e678.
     

     >> Share

     
     
162. GILL D, Vujkovic M
     The Potential of Genetic Data for Prioritizing Drug Repurposing Efforts.
     Neurology. 2022;99:267-268.
     

     >> Share

     
     
163. CROTTY GF, Keavney JL, Alcalay RN, Marek K, et al
     Planning for Prevention of Parkinson Disease: Now Is the Time.
     Neurology. 2022;99.
     

     >> Share

     
     
164. PIAZZA F, Caminiti SP, Zedde M, Presotto L, et al
     Association of Microglial Activation With Spontaneous ARIA-E and Cerebrospinal Fluid Levels of Anti-A Autoantibodies.
     Neurology. 2022 Aug 8. pii: WNL.0000000000200892.
     

     >> Share

     
     
165. AKINCI M, Pena-Gomez C, Operto G, Fuentes-Julian S, et al
     Pre-pandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults.
     Neurology. 2022 Aug 2. pii: WNL.0000000000200948.
     

     >> Share

     
     
166. CEDRES N, Ferreira D, Nemy M, Machado A, et al
     Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals.
     Neurology. 2022 Aug 2. pii: WNL.0000000000200930.
     

     >> Share

     
     July 2022
167. SHAHIM P, Zetterberg H, Simren J, Ashton NJ, et al
     Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes.
     Neurology. 2022;99:e347-e354.
     

     >> Share

     
     
168. SCHINDLER SE, Karikari TK, Ashton NJ, Henson RL, et al
     Effect of Race on Prediction of Brain Amyloidosis by Plasma Abeta42/Abeta40, Phosphorylated Tau, and Neurofilament Light.
     Neurology. 2022;99:e245-e257.
     

     >> Share

     
     
169. BORLAND E, Edgar C, Stomrud E, Cullen N, et al
     Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.
     Neurology. 2022 Jul 14. pii: WNL.0000000000200817.
     

     >> Share

     
     
170. WYNN M
     My First Patient With Alzheimer's.
     Neurology. 2022 Jul 14. pii: WNL.0000000000201087.
     

     >> Share

     
     
171. KEUSS SE, Coath W, Nicholas JM, Poole T, et al
     Associations of beta-Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort.
     Neurology. 2022;99:e129-e141.
     

     >> Share

     
     June 2022
172. MONTINE TJ, Corrada MM, Kawas C, Bukhari S, et al
     Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest-Old.
     Neurology. 2022 Jun 15. pii: WNL.0000000000200832.
     

     >> Share

     
     
173. PETERSEN KK, Lipton RB, Grober E, Davatzikos C, et al
     Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults: A Machine Learning Approach Using A4 Data.
     Neurology. 2022;98:e2425-e2435.
     

     >> Share

     
     
174. YANG JJ, Keohane LM, Pan X, Qu R, et al
     Association of Healthy Lifestyles with Risk of Alzheimer Disease and Related Dementias in Low-Income Black and White Americans.
     Neurology. 2022 Jun 13. pii: WNL.0000000000200774.
     

     >> Share

     
     
175. TANG B, Wang Y, Jiang X, Thambisetty M, et al
     Genetic Variation in Targets of Anti-diabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.
     Neurology. 2022 Jun 2. pii: WNL.0000000000200771.
     

     >> Share

     
     May 2022
176. KUMAR A, Janelidze S, Stomrud E, Palmqvist S, et al
     beta-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.
     Neurology. 2022 May 31. pii: WNL.0000000000200605.
     

     >> Share

     
     
177. DUMURGIER J, Sabia S, Zetterberg H, Teunissen C, et al
     Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging.
     Neurology. 2022 May 26. pii: WNL.0000000000200735.
     

     >> Share

     
     
178. MOHANTY R, Ferreira D, Frerich S, Muehlboeck JS, et al
     Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease.
     Neurology. 2022 May 24. pii: WNL.0000000000200573.
     

     >> Share

     
     
179. MCGIRR A, Nathan S, Ghahremani M, Gill S, et al
     Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms.
     Neurology. 2022;98:e2132-e2139.
     

     >> Share

     
     
180. XICOTA L, Gyorgy B, Grenier-Boley B, Lecoeur A, et al
     Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults.
     Neurology. 2022 May 23. pii: WNL.0000000000200544.
     

     >> Share

     
     
181. TOLLER G, Cobigo Y, Ljubenkov PA, Appleby BS, et al
     Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia.
     Neurology. 2022 May 18. pii: WNL.0000000000200582.
     

     >> Share

     
     
182. FARNSWORTH VON CEDERWALD B, Josefsson M, Wahlin A, Nyberg L, et al
     Association of Cardiovascular Risk Trajectory With Cognitive Decline and Incident Dementia.
     Neurology. 2022;98:e2013-e2022.
     

     >> Share

     
     
183. LI Z, Heckman MG, Kanekiyo T, Martens YA, et al
     Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment.
     Neurology. 2022;98:e2036-e2045.
     

     >> Share

     
     
184. ASKEN BM, Tanner JA, VandeVrede L, Mantyh WG, et al
     Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.
     Neurology. 2022 May 16. pii: WNL.0000000000200678.
     

     >> Share

     
     
185. AGOSTA F, Filippi M
     Natural Speech Analysis: A Window Into Alzheimer Disease Phenotypes.
     Neurology. 2022 May 4. pii: WNL.0000000000200843.
     

     >> Share

     
     
186. BEYDOUN MA, Beydoun HA, Fanelli-Kuczmarski MT, Weiss J, et al
     Association of Serum Antioxidant Vitamins and Carotenoids With Incident Alzheimer Disease and All-Cause Dementia Among US Adults.
     Neurology. 2022 May 4. pii: WNL.0000000000200289.
     

     >> Share

     
     April 2022
187. CHO S, Quilico Cousins KA, Shellikeri S, Ash S, et al
     Lexical and Acoustic Speech Features Relating to Alzheimer Disease Pathology.
     Neurology. 2022 Apr 29. pii: WNL.0000000000200581.
     

     >> Share

     
     
188. WHITWELL J, Martin PR, Graff-Radford J, Machulda M, et al
     Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease.
     Neurology. 2022 Apr 28. pii: WNL.0000000000200336.
     

     >> Share

     
     
189. VOGEL JW, Tosun D
     Multiple Cortical to Striatal Accumulation Trajectories of beta-Amyloid: Do All Roads Lead to Rome?
     Neurology. 2022;98:695-696.
     

     >> Share

     
     
190. COLLIJ LE, Salvado G, Wottschel V, Mastenbroek SE, et al
     Spatial-Temporal Patterns of beta-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis.
     Neurology. 2022;98:e1692-e1703.
     

     >> Share

     
     
191. BEAUDIN AE, McCreary CR, Mazerolle EL, Gee M, et al
     Cerebrovascular Reactivity Across the Entire Brain in Cerebral Amyloid Angiopathy.
     Neurology. 2022;98:e1716-e1728.
     

     >> Share

     
     
192. ARANHA MR, Fortea J, Carmona-Iragui M
     Cerebral Amyloid Angiopathy-Related Inflammation in Down Syndrome-Related Alzheimer Disease.
     Neurology. 2022 Apr 25. pii: WNL.0000000000200704.
     

     >> Share

     
     
193. FRANK B, Ally M, Tripodis Y, Puzo C, et al
     Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease.
     Neurology. 2022 Apr 20. pii: WNL.0000000000200304.
     

     >> Share

     
     
194. BEAMAN C, Kozii K, Hilal S, Liu M, et al
     Cerebral Microbleeds, Cerebral Amyloid Angiopathy, and Their Relationships to Quantitative Markers of Neurodegeneration.
     Neurology. 2022;98:e1605-e1616.
     

     >> Share

     
     
195. DIFRANCESCO JC, Stanzani L
     Increased Brain Volume: A Novel Biomarker of Neurodegeneration?
     Neurology. 2022;98:649-650.
     

     >> Share

     
     
196. SIBLE IJ, Nation DA
     Visit-to-Visit Blood Pressure Variability and CSF Alzheimer Disease Biomarkers in Cognitively Unimpaired and Mildly Impaired Older Adults.
     Neurology. 2022 Apr 13. pii: WNL.0000000000200302.
     

     >> Share

     
     
197. GRAFF-RADFORD J, Josephs K
     Author Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
     Neurology. 2022;98:644.
     

     >> Share

     
     
198. DASHEIFF R
     Reader Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
     Neurology. 2022;98:643.
     

     >> Share

     
     
199. SIEGLER JE 3RD, Galetta S
     Editors' Note: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
     Neurology. 2022;98:643.
     

     >> Share

     
     
200. FARRELL ME, Papp KV, Buckley RF, Jacobs HIL, et al
     Association of Emerging beta-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.
     Neurology. 2022;98:e1512-e1524.
     

     >> Share

     
     
201. TIDEMAN P, Stomrud E, Leuzy A, Mattsson-Carlgren N, et al
     Association of beta-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
     Neurology. 2022;98:e1525-e1533.
     

     >> Share

     
     
202. GAUTHREAUX KM, Teylan MA, Katsumata Y, Mock C, et al
     Limbic-Predominant Age-Related TDP-43 Encephalopathy: Medical and Pathologic Factors Associated With Comorbid Hippocampal Sclerosis.
     Neurology. 2022;98:e1422-e1433.
     

     >> Share

     
     
203. GU Y, Kociolek A, Fernandez KK, Cosentino SA, et al
     Clinical Trajectories at the End of Life in Dementia Patients With Alzheimer Disease and Lewy Body Neuropathologic Changes.
     Neurology. 2022 Apr 4. pii: WNL.0000000000200259.
     

     >> Share

     
     March 2022
204. GUAN Y, Ebrahimzadeh SA, Cheng CH, Chen W, et al
     Association of Diabetes and Hypertension With Brain Structural Integrity and Cognition in the Boston Puerto Rican Health Study Cohort.
     Neurology. 2022 Mar 30. pii: WNL.0000000000200120.
     

     >> Share

     
     
205. ZAMMIT AR, Yu L, Petyuk V, Schneider JA, et al
     Cortical Proteins and Individual Differences in Cognitive Resilience in Older Adults.
     Neurology. 2022;98:e1304-e1314.
     

     >> Share

     
     
206. SALINAS J, Beiser AS, Samra JK, O'Donnell A, et al
     Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline.
     Neurology. 2022;98:e1337-e1348.
     

     >> Share

     
     
207. PETERSEN RC
     Detecting Alzheimer Disease Clinically: How Early Can We Go?
     Neurology. 2022 Mar 25. pii: WNL.0000000000200172.
     

     >> Share

     
     
208. VAN DE BEEK M, Ooms FAH, Ebenau JL, Barkhof F, et al
     Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies.
     Neurology. 2022;98:e1262-e1272.
     

     >> Share

     
     
209. VAN LOENHOUD AC, Groot C, Bocancea DI, Barkhof F, et al
     Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum.
     Neurology. 2022 Mar 21. pii: WNL.0000000000200116.
     

     >> Share

     
     
210. JOSEPHS KA, Weigand SD, Whitwell J
     Characterizing Amyloid Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.
     Neurology. 2022 Mar 21. pii: WNL.0000000000200287.
     

     >> Share

     
     
211. HESHMATOLLAH A, Fani L, Koudstaal PJ, Ghanbari M, et al
     Plasma Amyloid Beta, Total-Tau and Neurofilament Light Chain Levels and the Risk of Stroke: A Prospective Population-Based Study.
     Neurology. 2022 Mar 1. pii: WNL.0000000000200004.
     

     >> Share

     
     February 2022
212. DAY GS, Scarmeas N, Dubinsky R, Coerver K, et al
     Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: Report of the AAN Guidelines Subcommittee.
     Neurology. 2022 Feb 23. pii: WNL.0000000000200176.
     

     >> Share

     
     
213. GROBER E, Lipton RB, Sperling RA, Papp KV, et al
     Associations of Stages of Objective Memory Impairment (SOMI) with Amyloid PET and Structural MRI: The A4 Study.
     Neurology. 2022 Feb 23. pii: WNL.0000000000200046.
     

     >> Share

     
     
214. MATTSSON-CARLGREN N, Grinberg LT, Boxer A, Ossenkoppele R, et al
     Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
     Neurology. 2022 Feb 16. pii: WNL.0000000000200040.
     

     >> Share

     
     
215. CHU WT, Wang WE, Zaborszky L, Golde TE, et al
     Association of Cognitive Impairment With Free Water in the Nucleus Basalis of Meynert and Locus Coeruleus to Transentorhinal Cortex Tract.
     Neurology. 2022;98:e700-e710.
     

     >> Share

     
     
216. EBENAU JL, Pelkmans W, Verberk IMW, Verfaillie S, et al
     Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
     Neurology. 2022 Feb 2. pii: WNL.0000000000200035.
     

     >> Share

     
     January 2022
217. BOWN CW, Carare RO, Schrag MS, Jefferson AL, et al
     Physiology and Clinical Relevance of Enlarged Perivascular Spaces in the Aging Brain.
     Neurology. 2022;98:107-117.
     

     >> Share

     
     
218. WHITTINGTON MD, Campbell JD, Rind D, Fluetsch N, et al
     Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease.
     Neurology. 2022 Jan 12. pii: WNL.0000000000013314.
     

     >> Share

     
     
219. BALLARINI T, Melo van Lent D, Wagner M
     Author Response: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
     Neurology. 2022;98:89-90.
     

     >> Share

     
     
220. GANESH A, Galetta S
     Editors' Note: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
     Neurology. 2022;98:88.
     

     >> Share

     
     
221. BRENNER SR
     Reader Response: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
     Neurology. 2022;98:88-89.
     

     >> Share

     
     
222. DA SILVA SOYOMBO NK, Rocha EL, Xavier LB, Oliveira RA, et al
     Biomarkers for Differential Diagnosis Between Chronic Traumatic Encephalopathy and Alzheimer Disease: A Systematic Review.
     Neurology. 2022;98.
     

     >> Share

     
     December 2021
223. YOO HS, Jeon S, Cavedo E, Ko M, et al
     Association of beta-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra.
     Neurology. 2021 Dec 30. pii: WNL.0000000000013277.
     

     >> Share

     
     
224. CULLEN N, Janelidze S, Palmqvist S, Stomrud E, et al
     Association of CSF Abeta38 Levels With Risk of Alzheimer Disease-Related Decline.
     Neurology. 2021 Dec 22. pii: WNL.0000000000013228.
     

     >> Share

     
     
225. YU L, Boyle PA, Wingo AP, Yang J, et al
     Neuropathologic Correlates of Human Cortical Proteins in Alzheimer Disease and Related Dementias.
     Neurology. 2021 Dec 22. pii: WNL.0000000000013252.
     

     >> Share

     
     
226. LI Y, Schindler SE, Bollinger JG, Ovod V, et al
     Validation of Plasma Amyloid-beta 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
     Neurology. 2021 Dec 14. pii: WNL.0000000000013211.
     

     >> Share

     
     November 2021
227. SMIRNOV DS, Salmon DP, Galasko D, Goodwill VS, et al
     Association of Neurofibrillary Tangle Distribution With Age at Onset-Related Clinical Heterogeneity in Alzheimer Disease: An Autopsy Study.
     Neurology. 2021 Nov 22. pii: WNL.0000000000013107.
     

     >> Share

     
     
228. ACOSTA LM
     I Wasn't There: Caring for a Patient With Trisomy 21, Alzheimer Disease, and Epilepsy Until His Final Days With COVID-19.
     Neurology. 2021 Nov 22. pii: WNL.0000000000013109.
     

     >> Share

     
     
229. CHIONG W, Tolchin BD, Bonnie RJ, Busl K, et al
     Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement.
     Neurology. 2021 Nov 17. pii: WNL.0000000000013053.
     

     >> Share

     
     
230. KUSCHPEL MS
     Reader Response: Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
     Neurology. 2021;97:964-965.
     

     >> Share

     
     
231. SCHELBAUM E, Loughlin L, Jett S, Zang C, et al
     Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife.
     Neurology. 2021 Nov 3. pii: WNL.0000000000012941.
     

     >> Share

     
     October 2021
232. LEUZY A, Janelidze S, Mattsson-Carlgren N, Palmqvist S, et al
     Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
     Neurology. 2021;97:e1681-e1694.
     

     >> Share

     
     September 2021
233. KIM YJ, Karceski S
     Alzheimer Disease and Mood.
     Neurology. 2021;97:e1363-e1366.
     

     >> Share

     
     
234. EDMONDS EC, Smirnov DS, Thomas KR, Graves LV, et al
     Data-Driven vs Consensus Diagnosis of MCI: Enhanced Sensitivity for Detection of Clinical, Biomarker, and Neuropathologic Outcomes.
     Neurology. 2021;97:e1288-e1299.
     

     >> Share

     
     
235. MILA-ALOMA M, Brinkmalm A, Ashton NJ, Kvartsberg H, et al
     CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study.
     Neurology. 2021 Sep 23. pii: WNL.0000000000012853.
     

     >> Share

     
     
236. GARNIER-CRUSSARD A, Krolak-Salmon P
     Reader Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
     Neurology. 2021;97:608.
     

     >> Share

     
     
237. THERRIAULT J, Pascoal T, Gauthier S, Rosa-Neto P, et al
     Author Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
     Neurology. 2021;97:609.
     

     >> Share

     
     
238. JEONG SH, Kim HR, Kim J, Kim H, et al
     Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment.
     Neurology. 2021;97:e1110-e1122.
     

     >> Share

     
     
239. HERSHEY LA, Tarawneh R
     Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?
     Neurology. 2021;97:517-518.
     

     >> Share

     
     
240. SCHINDLER S, Li Y, Buckles VD, Gordon BA, et al
     Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.
     Neurology. 2021 Sep 9. pii: WNL.0000000000012775.
     

     >> Share

     
     
241. BUCIUC M, Josephs KA, Jones DT, Whitwell JL, et al
     Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
     Neurology. 2021 Sep 9. pii: WNL.0000000000012783.
     

     >> Share

     
     
242. MCCARTER S, Lesnick TG, Lowe V, Mielke MM, et al
     Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-beta PET Signal.
     Neurology. 2021 Sep 9. pii: WNL.0000000000012770.
     

     >> Share

     
     August 2021
243. FRISON E, Proust-Lima C, Mangin JF, Habert MO, et al
     Diabetes Mellitus and Cognition: Pathway Analysis in the MEMENTO Cohort.
     Neurology. 2021;97:e836-e848.
     

     >> Share

     
     
244. SANDERS AE
     A Century-Old Problem: Cognition and Neuropsychiatric Symptoms in Alzheimer Disease.
     Neurology. 2021 Aug 20. pii: WNL.0000000000012616.
     

     >> Share

     
     
245. EIKELBOOM WS, van den Berg E, Singleton EH, Baart SJ, et al
     Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations.
     Neurology. 2021 Aug 19. pii: WNL.0000000000012598.
     

     >> Share

     
     
246. LI J
     Alzheimer's Villanelle.
     Neurology. 2021 Aug 10. pii: WNL.0000000000012612.
     

     >> Share

     
     
247. PETERSEN RC
     Mild Cognitive Impairment Criteria in Alzheimer's Disease Neuroimaging Initiative: Meeting Biological Expectations.
     Neurology. 2021 Aug 2. pii: WNL.0000000000012588.
     

     >> Share

     
     July 2021
248. TAO Q, Alvin Ang TF, Akhter-Khan SC, Itchapurapu IS, et al
     Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous Apolipoprotein E varepsilon4 Carriers.
     Neurology. 2021 Jul 15. pii: WNL.0000000000012512.
     

     >> Share

     
     
249. BOCANCEA DI, Catharina van Loenhoud A, Groot C, Barkhof F, et al
     Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis.
     Neurology. 2021 Jul 15. pii: WNL.0000000000012499.
     

     >> Share

     
     
250. GROTHE MJ, Moscoso A, Ashton NJ, Karikari TK, et al
     Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy.
     Neurology. 2021 Jul 15. pii: WNL.0000000000012513.
     

     >> Share

     
     
251. POGGESI A
     Resilience and Resistance in Aging and Alzheimer Disease: Another Step to Fill the Gap Between Clinicians and Researchers.
     Neurology. 2021 Jul 15. pii: WNL.0000000000012500.
     

     >> Share

     
     
252. WILSON RS, Wang T, Yu L, Grodstein F, et al
     Cognitive Activity and Onset Age of Incident Alzheimer Disease Dementia.
     Neurology. 2021 Jul 14. pii: WNL.0000000000012388.
     

     >> Share

     
     
253. SALLOWAY S, Cummings J
     Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease.
     Neurology. 2021 Jul 7. pii: WNL.0000000000012451.
     

     >> Share

     
     June 2021
254. BUCIUC M, Duffy JR, Machulda MM, Graff-Radford J, et al
     Clinical, Imaging, and Pathologic Characteristics of Patients With Right Versus Left Hemisphere-Predominant Logopenic Progressive Aphasia.
     Neurology. 2021 Jun 4. pii: WNL.0000000000012322.
     

     >> Share

     
     
255. JUTTEN RJ, Sikkes SAM, Van der Flier WM, Scheltens P, et al
     Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity.
     Neurology. 2021;96:e2673-e2684.
     

     >> Share

     
     
256. BUCKLEY RF, Knopman DS
     Cognitive Heterogeneity in Alzheimer Clinical Trials: Harnessing Noise to Achieve Meaningfulness.
     Neurology. 2021;96:1017-1018.
     

     >> Share

     
     May 2021
257. HUGHES TM, Hajjar I
     Is Late-onset Alzheimer Disease Spelled "ATV(N)"?
     Neurology. 2021 May 24. pii: WNL.0000000000012259.
     

     >> Share

     
     
258. DONADIO V, Wang Z, Incensi A, Rizzo G, et al
     In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC.
     Neurology. 2021;96:e2513-e2524.
     

     >> Share

     
     
259. FRIEDMAN LG, McKeehan N, Hara Y, Cummings JL, et al
     Value-Generating Exploratory Trials in Neurodegenerative Dementias.
     Neurology. 2021;96:944-954.
     

     >> Share

     
     
260. MAYBLYUM DV, Becker JA, Jacobs HIL, Buckley RF, et al
     Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.
     Neurology. 2021 May 5. pii: WNL.0000000000012108.
     

     >> Share

     
     
261. BALLARINI T, Melo van Lent D, Brunner J, Schroder A, et al
     Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old Age.
     Neurology. 2021 May 5. pii: WNL.0000000000012067.
     

     >> Share

     
     
262. BELLAVER B, Ferrari-Souza JP, Uglione da Ros L, Carter SF, et al
     Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis.
     Neurology. 2021 May 5. pii: WNL.0000000000012109.
     

     >> Share

     
     
263. HAZRATI LN, Schwab N
     Embracing the Unknown in the Diagnosis of Traumatic Encephalopathy Syndrome.
     Neurology. 2021;96:835-836.
     

     >> Share

     
     April 2021
264. BOERWINKLE AH, Wisch JK, Chen CD, Gordon BA, et al
     Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease.
     Neurology. 2021 Apr 30. pii: WNL.0000000000012123.
     

     >> Share

     
     
265. KARCESKI S
     The Effects of Long-term Medication Use in Alzheimer Disease.
     Neurology. 2021;96:e2247-e2250.
     

     >> Share

     
     
266. XU H, Garcia-Ptacek S, Jonsson L, Wimo A, et al
     Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
     Neurology. 2021;96:e2220-e2230.
     

     >> Share

     
     
267. ROBERTS G, Durcan Mrcpi R, Donaghy PC, Lawley S, et al
     Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies.
     Neurology. 2021 Apr 21. pii: WNL.0000000000012060.
     

     >> Share

     
     
268. HAMILTON CA, Matthews FE, Donaghy PC, Taylor JP, et al
     Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease.
     Neurology. 2021 Apr 19. pii: WNL.0000000000012024.
     

     >> Share

     
     
269. HOWARD E, Irwin DJ, Rascovsky K, Nevler N, et al
     Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.
     Neurology. 2021;96:e1855-e1864.
     

     >> Share

     
     March 2021
270. QIAN J, Betensky RA, Hyman BT, Serrano-Pozo A, et al
     Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease.
     Neurology. 2021 Mar 26. pii: WNL.0000000000011883.
     

     >> Share

     
     
271. GOTTESMAN RF, Hamilton R
     Recruiting Diverse Populations in Clinical Trials: How Do We Overcome Selection Bias?
     Neurology. 2021;96:509-510.
     

     >> Share

     
     
272. KANG SH, Kim ME, Jang H, Kwon H, et al
     Amyloid Positivity in Alzheimer/Subcortical-Vascular Spectrum.
     Neurology. 2021 Mar 15. pii: WNL.0000000000011833.
     

     >> Share

     
     
273. SMIRNOV DS, Galasko D, Hiniker A, Edland S, et al
     Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease.
     Neurology. 2021 Mar 15. pii: WNL.0000000000011772.
     

     >> Share

     
     
274. BARKHOF BF, Pressman PS
     Time Is of the Essence: Early Detection of Incipient Alzheimer Pathology.
     Neurology. 2021 Mar 2. pii: WNL.0000000000011739.
     

     >> Share

     
     February 2021
275. ROBINSON-PAPP J, Saylor D
     HIV in the Brain: From Devastating Dementia to White Matter Hyperintensities.
     Neurology. 2021 Feb 26. pii: WNL.0000000000011735.
     

     >> Share

     
     
276. HUYNH K, Piguet O, Kwok J, Dobson-Stone C, et al
     Clinical and Biological Correlates of White Matter Hyperintensities in Patients with Behavioral-variant Frontotemporal Dementia and Alzheimer Disease.
     Neurology. 2021 Feb 17. pii: WNL.0000000000011638.
     

     >> Share

     
     
277. THERRIAULT J, Pascoal TA, Benedet AL, Tissot C, et al
     Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
     Neurology. 2021;96:e975-e985.
     

     >> Share

     
     
278. RENTZ DM, Papp KV, Mayblyum DV, Sanchez JS, et al
     Association of Digital Clock Drawing with PET Amyloid and Tau Pathology in Normal Older Adults.
     Neurology. 2021 Feb 15. pii: WNL.0000000000011697.
     

     >> Share

     
     
279. DETERS K, Napolioni V, Sperling RA, Greicius MD, et al
     Amyloid PET imaging in self-identified non-Hispanic Blacks from the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.
     Neurology. 2021 Feb 10. pii: WNL.0000000000011599.
     

     >> Share

     
     
280. FERREIRA D, Nordberg A, Westman E
     Author Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
     Neurology. 2021;96:238.
     

     >> Share

     
     
281. ULEMAN JF, Melis RJF, Olde Rikkert MGM
     Reader Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
     Neurology. 2021;96:237-238.
     

     >> Share

     
     
282. GANESH A, Galetta S
     Editors' Note: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
     Neurology. 2021;96:237.
     

     >> Share

     
     January 2021
283. JOSEPH-MATHURIN N, Wang G, Kantarci K, Jack CR Jr, et al
     Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease.
     Neurology. 2021 Jan 25. pii: WNL.0000000000011542.
     

     >> Share

     
     
284. SAJJADI SA, Ash S, Cappa S
     Glass half full: Preservation of memory in Alzheimer-related primary progressive aphasia.
     Neurology. 2021 Jan 13. pii: WNL.0000000000011404.
     

     >> Share

     
     
285. MESULAM MM, Coventry C, Kuang A, Bigio EH, et al
     Memory resilience in Alzheimer's disease with primary progressive aphasia.
     Neurology. 2021 Jan 13. pii: WNL.0000000000011397.
     

     >> Share

     
     
286. BLAZHENETS G, Frings L, Ma Y, Sorensen A, et al
     Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration.
     Neurology. 2021 Jan 6. pii: WNL.0000000000011521.
     

     >> Share

     
     
287. JAGUST WJ, Landau SM
     Temporal Dynamics of Beta-amyloid Accumulation in Aging and Alzheimer's Disease.
     Neurology. 2021 Jan 6. pii: WNL.0000000000011524.
     

     >> Share

     
     
288. TRELLE AN, Carr VA, Wilson EN, Swarovski MS, et al
     Association of CSF Biomarkers with Hippocampal-dependent Memory in Preclinical Alzheimer Disease.
     Neurology. 2021 Jan 6. pii: WNL.0000000000011477.
     

     >> Share

     
     
289. THERRIAULT J, Pascoal TA, Savard M, Benedet AL, et al
     Topographic Distribution of Amyloid-beta, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease.
     Neurology. 2021;96:e81-e92.
     

     >> Share

     
     December 2020
290. KNOPMAN DS, Jagust WJ
     Alzheimer Disease Spectrum: Syndrome and Etiology from Clinical and PET Imaging Perspectives.
     Neurology. 2020 Dec 22. pii: WNL.0000000000011415.
     

     >> Share

     
     
291. KOYAMA AK, Irwin DJ
     Alzheimer disease biomarker profiles in dementia with Lewy bodies: Does A plus T spell D-L-B?
     Neurology. 2020;95:1076-1077.
     

     >> Share

     
     
292. GICAS KM, Honer WG, Wilson RS, Boyle PA, et al
     Association of serial position scores on memory tests and hippocampal-related neuropathologic outcomes.
     Neurology. 2020;95:e3303-e3312.
     

     >> Share

     
     
293. PETTIGREW C, Soldan A, Wang J, Wang MC, et al
     Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline.
     Neurology. 2020;95:e3093-e3103.
     

     >> Share

     
     
294. PALMQVIST S, Eshaghi A
     Spatial distribution of tau and beta-amyloid pathologies and their role in different Alzheimer's disease phenotypes.
     Neurology. 2020 Dec 1. pii: WNL.0000000000011272.
     

     >> Share

     
     
295. LA JOIE R, Visani AV, Lesman-Segev OH, Baker SL, et al
     Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET.
     Neurology. 2020 Dec 1. pii: WNL.0000000000011270.
     

     >> Share

     
     November 2020
296. KARCESKI S
     How a buildup of abnormal proteins in the brain may be the key to understanding Alzheimer disease.
     Neurology. 2020;95:e2951-e2953.
     

     >> Share

     
     
297. YOUNAN D, Wang X, Casanova R, Barnard R, et al
     PM2.5 associated with gray matter atrophy reflecting increased Alzheimers risk in older women.
     Neurology. 2020 Nov 18. pii: WNL.0000000000011149.
     

     >> Share

     
     
298. ILLAN-GALA I, Lleo A, Karydas A, Staffaroni AM, et al
     Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer's disease.
     Neurology. 2020 Nov 16. pii: WNL.0000000000011226.
     

     >> Share

     
     
299. GRAFF-RADFORD J, Knopman D, Jones D
     Author response: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
     Neurology. 2020;95:846.
     

     >> Share

     
     
300. ALLALI G, Laticevschi T
     Reader response: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
     Neurology. 2020;95:845-846.
     

     >> Share

     
     
301. SIEGLER JE 3RD, Galetta S
     Editors' note: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
     Neurology. 2020;95:845.
     

     >> Share

     
     October 2020
302. KIM HR, Lee T, Choi JK, Jeong Y, et al
     Genetic variants beyond amyloid and tau associated with cognitive decline: A cohort study.
     Neurology. 2020;95:e2366-e2377.
     

     >> Share

     
     
303. WEIGAND AJ, Bondi MW, Thomas KR, Campbell NL, et al
     Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults.
     Neurology. 2020;95:e2295-e2304.
     

     >> Share

     
     
304. KERCHNER GA, Filippi M
     Abeta-PET pathology accumulation index: Ready for the clinic?
     Neurology. 2020 Oct 19. pii: WNL.0000000000011060.
     

     >> Share

     
     
305. LEUZY A, Lilja J, Buckley CJ, Ossenkoppele R, et al
     Derivation and utility of an Abeta-PET pathology accumulation index to estimate Abeta load.
     Neurology. 2020 Oct 19. pii: WNL.0000000000011031.
     

     >> Share

     
     
306. BENNETT DA, Knopman DS
     Extending Alzheimer disease biomarker studies into the Hispanic community.
     Neurology. 2020;95:665-666.
     

     >> Share

     
     
307. NAG S, Barnes LL, Yu L, Wilson RS, et al
     Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents.
     Neurology. 2020;95:e2056-e2064.
     

     >> Share

     
     
308. GERTJE EC, van Westen D, Panizo C, Mattsson-Carlgren N, et al
     Association of enlarged perivascular spaces and measures of small vessel and Alzheimers disease.
     Neurology. 2020 Oct 12. pii: WNL.0000000000011046.
     

     >> Share

     
     
309. KAPASI A, Yu L, Boyle PA, Barnes LL, et al
     Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging.
     Neurology. 2020;95:e1951-e1962.
     

     >> Share

     
     
310. CATRICALA E, Polito C, Presotto L, Esposito V, et al
     Neural correlates of naming errors across different neurodegenerative diseases: A FDG-PET study.
     Neurology. 2020 Oct 1. pii: WNL.0000000000010967.
     

     >> Share

     
     September 2020
311. HANES J, Kovac A, Kvartsberg H, Kontsekova E, et al
     Evaluation of a novel immunoassay to detect p-Tau Thr127 in the CSF to distinguish Alzheimer disease from other dementias.
     Neurology. 2020 Sep 24. pii: WNL.0000000000010814.
     

     >> Share

     
     
312. BRENOWITZ WD, Besser LM, Kukull WA, Keene CD, et al
     Clinician-judged hearing impairment and associations with neuropathologic burden.
     Neurology. 2020;95:e1640-e1649.
     

     >> Share

     
     
313. SCHREIBER S, DiFrancesco JC
     Impaired occipital cerebrovascular reactivity as a biomarker for vascular beta-amyloid.
     Neurology. 2020;95:415-416.
     

     >> Share

     
     
314. GUZMAN-VELEZ E, Martinez J, Papp K, Baena A, et al
     Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers.
     Neurology. 2020;95:e1312-e1321.
     

     >> Share

     
     August 2020
315. KIM JW, Byun MS, Lee JH, Yi D, et al
     Serum albumin and beta-amyloid deposition in the human brain.
     Neurology. 2020;95:e815-e826.
     

     >> Share

     
     
316. VAN DER ZANDE JJ, Gouw AA, van Steenoven I, van de Beek M, et al
     Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies.
     Neurology. 2020;95:e662-e670.
     

     >> Share

     
     July 2020
317. COLLIJ LE, Heeman F, Salvado G, Ingala S, et al
     Multi-tracer model for staging cortical amyloid deposition using PET imaging.
     Neurology. 2020 Jul 16. pii: WNL.0000000000010256.
     

     >> Share

     
     
318. EBENAU JL, Timmers T, Wesselman LMP, Verberk IMW, et al
     ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
     Neurology. 2020;95:e46-e58.
     

     >> Share

     
     
319. SAKAE N, Santos OA, Pedraza O, Litvan I, et al
     Clinical and pathologic features of cognitive-predominant corticobasal degeneration.
     Neurology. 2020;95:e35-e45.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share